Identification of T-cell epitopes for cancer immunotherapy (Q36870592)

16 August 2017

1 reference

title

Identification of T-cell epitopes for cancer immunotherapy (English)

1 reference

16 August 2017

1 reference

Kessler JH

1

1 reference

PubMed ID

17611570

16 August 2017

Melief CJ

series ordinal

2

1 reference

16 August 2017

5 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

21

1 reference

16 August 2017

9

1 reference

16 August 2017

1859-1874

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404787

16 August 2017

0 references

cites work

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Structure of the human class I histocompatibility antigen, HLA-A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Processing and presentation of tumor antigens and vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Adoptive transfer of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Dendritic cells: a journey from laboratory to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Concomitant helper response rescues otherwise low avidity CD8+ memory CTLs to become efficient effectors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Unique human tumor antigens: immunobiology and use in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The turnover kinetics of major histocompatibility complex peptides of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of human tumor antigens and its implications for diagnosis and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An antigenic peptide produced by peptide splicing in the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Immune recognition of a human renal cancer antigen through post-translational protein splicing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Serial analysis of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Bcr-Abl variants: biological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cooperation of hTERT, SV40 T antigen and oncogenic Ras in tumorigenesis: a cell transplantation model using bovine adrenocortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Towards patient-specific tumor antigen selection for vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of a graft versus host disease-associated human minor histocompatibility antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Post-translational modifications of naturally processed MHC-binding epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An antigen produced by splicing of noncontiguous peptides in the reverse order.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Complexity, contradictions, and conundrums: studying post-proteasomal proteolysis in HLA class I antigen presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Making sense of mass destruction: quantitating MHC class I antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

IMGT/HLA database--a sequence database for the human major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Using the World Wide Web for predicting CTL epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Immunoinformatics comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A community resource benchmarking predictions of peptide binding to MHC-I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

p53, a potential target for tumor-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Random screening of proteins for HLA-A*0201-binding nine-amino acid peptides is not sufficient for identifying CD8 T cell epitopes recognized in the context of HLA-A*0201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of naturally processed HLA-A2--restricted proinsulin epitopes by reverse immunology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An algorithm for the prediction of proteasomal cleavages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Prediction of proteasome cleavage motifs by neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Specificity of the proteasome and the TAP transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

PRED(TAP): a system for prediction of peptide binding to the human transporter associated with antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Analysis and prediction of affinity of TAP binding peptides using cascade SVM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Prediction of CTL epitopes using QM, SVM and ANN techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Integrated modeling of the major events in the MHC class I antigen processing pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

EpiJen: a server for multistep T cell epitope prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

The immune epitope database and analysis resource: from vision to blueprint

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural ligands from HIV envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A cytosolic pathway for MHC class II-restricted antigen processing that is proteasome and TAP dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

SVMHC: a server for prediction of MHC-binding peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

ProPred: prediction of HLA-DR binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Proteomics: a technology-driven and technology-limited discovery science

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Contribution of mass spectrometry-based proteomics to immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Use of proteomics to define targets of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Diversity and recognition efficiency of T cell responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

The DRiP hypothesis decennial: support, controversy, refinement and extension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

HLA supertypes and supermotifs: a functional perspective on HLA polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Vaccination for treatment and prevention of cancer in animal models.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404787

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404787

1 reference

16 August 2017

1 reference

PubMed ID

17611570